Chang A B, Phelan P D, Carlin J B, Sawyer S M, Robertson C F
Department of Thoracic Medicine, University of Melbourne, Victoria, Australia.
Arch Dis Child. 1998 Jul;79(1):6-11. doi: 10.1136/adc.79.1.6.
To test the hypothesis that inhaled salbutamol or beclomethasone will reduce the frequency of cough in children with recurrent cough. A secondary aim was to determine if the presence of airway hyperresponsiveness (AHR) can predict the response.
Randomised, double blind, placebo controlled trial.
During a coughing phase, 43 children (age 6-17 years) with recurrent cough were randomised to receive inhaled salbutamol or placebo (phase I) for 5-7 days and then beclomethasone or placebo (phase II) for 4-5 weeks, and in a subgroup of children for 8-9 weeks. The children used an ambulatory cough meter, kept cough diaries, and performed the capsaicin cough sensitivity, hypertonic saline bronchoprovocation, and skin prick tests.
Salbutamol or beclomethasone had no effect on cough frequency or score, irrespective of the presence of AHR.
Most children with recurrent cough without other evidence of airway obstruction, do not have asthma and neither inhaled salbutamol nor beclomethasone is beneficial.
检验吸入沙丁胺醇或倍氯米松可降低复发性咳嗽患儿咳嗽频率的假设。次要目的是确定气道高反应性（AHR）的存在是否能预测反应。
随机、双盲、安慰剂对照试验。
在咳嗽期，43名复发性咳嗽患儿（6 - 17岁）被随机分为接受吸入沙丁胺醇或安慰剂（第一阶段）5 - 7天，然后接受倍氯米松或安慰剂（第二阶段）4 - 5周，部分儿童亚组为8 - 9周。患儿使用便携式咳嗽计，记录咳嗽日记，并进行辣椒素咳嗽敏感性、高渗盐水支气管激发试验和皮肤点刺试验。
无论是否存在AHR，沙丁胺醇或倍氯米松对咳嗽频率或评分均无影响。
大多数无其他气道阻塞证据的复发性咳嗽患儿没有哮喘，吸入沙丁胺醇和倍氯米松均无益处。
